T h e aim of this study was to construct a fusion protein from the cytokine granulocyte/macrophage colony-stimulating factor (GM-CSF) and a single-chain Fv fragment (scFv D29) and to investigate its potential to activate cells of the immune system against neuroblastoma cells expressing neural cell adhesion molecule (NCAM). Mammalian cell expression of the scFv D29-GM-CSF fusion protein was compared using a number of vectors, including retroviral and adenoviral vectors. T h e resultant fusion protein, expressed by HeLa cells, was found by ELISA to bind immobilized recombinant NCAM. Moreover, FACS analysis confirmed binding to the human neuroblastoma cell line SKNBE and a murine neuroblastoma cell line engineered to express the glycosylphosphatidylinositol form of human NCAM (N2A-rKNIE). T h e fusion protein was also found to stimulate the proliferation of the FDC-P1 haemopoietic cell line, which is dependent on GM-CSF (or interleukin 3) for continued growth. In vitro clonogenic assays indicated that scFv-GM-CSF could selectively induce
Introduction
Neuroblastoma is the most common solid malignant tumour in children after brain tumours, accounting for 40 yo of solid tumours presenting in the first 4 years of life. Neuroblastomas are derived from the neural crest, and have heterogeneous biological, genetic and morphological characteristics. T h e majority of patients that are diagnosed with neuroblastoma present at stage 4 (of the International Neuroblastoma Staging System), with metastatic disease that may initially respond to therapy, but which has a high probability of recurring. These patients have a low overall survival rate (less than 30%), despite undergoing surgery and moderately aggressive forms of cytotoxic therapy [l] .
Recent advances in the fields of antibody engineering and production have led to the design and use of a number of monoclonal antibodies for cancer therapy; for example, Herceptin, Mylotarg, Rituximab and Infliximal. In addition, systemic treatment with cytokines such as interleukin 2 and granulocyte/macrophage colony-stimulating factor (GM-CSF) has been shown to increase the immunogenicity of tumours. However, frequent side effects associated with toxicity limit the effectiveness of cytokine therapy in vivo. T h e conjugation of cytokines with monoclonal antibodies has been demonstrated to concentrate cytokines within the tumour microenvironment, thereby inducing tumour-specific immune responses and reducing overall systemic toxicity [2, 3] . In comparison with intact antibodies, single-chain Fc (scFv) molecules show increased tumour penetration, possibly as a consequence of their reduced size (27 kDa as opposed to 150 kDa for an IgG molecule) [4].
In this study, the gene for a humanized scFv (termed D29), derived from the anti-neuroblastoma cell adhesion molecule (NCAM) monoclonal antibody Eric-1, was linked to the murine G M -C S F gene and spliced into a number of vectors for expression of the scFv D29-GM-CSF fusion protein in mammalian cell lines. T h e resultant fusion protein was characterized and its potential to selectively induce growth inhibition of human neuroblastoma SKNBE cells by murine lymphoid cells in vitro investigated.
Results
Mammalian cell expression of the scFv D29-GM-CSF fusion protein was achieved using a number of vectors, including a retroviral vector (the KAT Figure I FACS analysis of the specific binding of the D29-GM-CSF fusion protein
Binding of D29-GM-CSF (grey line) and imlevant scFv-GM-CSF (known as B I .8; black line) fusion proteins to human neuroblastoma cell line (SKNBE), murine neuroblastoma cell line (N2A) and murine neuroblastoma-expressing human NCAM cell line (N2A-rKNIE).
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Figure 2
Growth-inhibition assay Target cells (SKNBE) were incubated with D29-GM-CSF. B I .E-GM-CSF or medium alone. Unbound fusion protein was washed off prior t o the addition of murine splenocytes, and the cells incubated for 8 days in Dulbecco's modified Eagle's medium/ 10% fetal calf serum at 37 "C under 5 % CO,. After incubation. remaining cells were trypsinized from the dish and counted (using Trypan Blue t o exclude dead cells). Target cells were distinguished from lymphoid cells by FACS analysis using an antibody against the lymphoid cells (antiLCD I I a, followed by an FITCconjugated secondary antibody). Bar I, target alone: bar 2, target+B I .8-GM-CSF: bar 3, target+D29-GM-CSF; bar 4, target+effector cells; bar 5, target+effector cells+B I .8-GM-CSF: bar 6, target+effector cells+D29-GM-CSF. Both the D29-GM-CSF and B1.8-GM-CSF fusion proteins were found to stimulate the proliferation of the FDC-PI haemopoietic cell line, which is dependent on GM-CSF (or interleukin 3) for continued growth. Furthermore, in vitro clonogenic assays using murine lymphoid cells isolated from spleen indicated that D29-GM-CSF could selectively induce growth inhibition of SKNBE cells (Figure 2 ). T h e results show that the addition of murine effector cells to the human neuroblastoma cell line induced a growth-inhibition effect (Figure 2 , bar no. 4), which was not unexpected. T h e effect was not significantly enhanced by the addition of an irrelevant scFv-GM-CSF fusion protein.
T h e addition of the anti-NCAM scFv-GM-CSF fusion protein did induce a small additional inhibition of growth compared with effectors alone ( P = 0.00658), or effectors and irrelevant fusion protein ( P = 0.00 184).
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Conclusions
The construction of an scFv-GM-CSF fusion protein targeting neuroblastoma cells expressing NCAM and its potential to inhibit the growth of a human neuroblastoma cell line was investigated. Retroviral and adenoviral vectors containing the gene for the fusion protein were constructed in order to overcome the complexity of large-scale protein production and purification. Adenoviruses in particular have been used in a number of animal models for in situ production of proteins [7, 8] . I n vitro clonogenic assays indicated that the anti-NCAM scFv-GM-CSF could selectively induce growth inhibition of human neuroblastoma cells by murine lymphoid cells.
